Leerink Partnrs Has Positive Outlook of KROS FY2028 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Analysts at Leerink Partnrs raised their FY2028 EPS estimates for Keros Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($2.03) per share for the year, up from their previous estimate of ($2.04). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ FY2029 earnings at ($2.69) EPS.

Several other brokerages have also recently issued reports on KROS. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Trading Down 3.4 %

Shares of NASDAQ KROS opened at $10.49 on Monday. The company has a 50 day simple moving average of $22.31 and a two-hundred day simple moving average of $43.44. The stock has a market cap of $424.95 million, a price-to-earnings ratio of -2.01 and a beta of 1.39. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the last quarter. KBC Group NV increased its position in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its stake in Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after purchasing an additional 1,033 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after purchasing an additional 1,100 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.